Double Time on Double Dipping: CMS Proposed Rule Puts Pressure On Medicaid Managed Care
This article was originally published in RPM Report
New rules on Medicaid managed care plans step up the reporting requirements for tracking drug utilization to assure timely and accurate rebate invoicing. They also include a potentially important clarification on who is responsible for preventing “double-dipping” on 340B products.
You may also be interested in...
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.